<DOC>
	<DOCNO>NCT00191828</DOCNO>
	<brief_summary>Olanzapine atypical antipsychotic agent indicate treatment schizophrenia moderate severe manic episode . Olanzapine among many antipsychotic agent associate weight gain . The mechanism antipsychotic drug-related weight gain know , although antagonism serotonin receptor , especially 5HT2C , histamine receptor hypothesize . The purpose study observe efficacy psychoeducational programme manage increased weight side effect olanzapine treatment . Interventions prevent weight gain associate olanzapine least include periodic monitoring recommendation change diet physical activity . This phase IV , randomise , parallel study subject previously treat olanzapine antipsychotic monotherapy , show increase B.M.I . &gt; 7 % begin antipsychotic treatment ( assessed routine visit ) . For first 12 week trial approximately 60 outpatient , enrol one site period one year , randomise 1:1 ratio 2 treatment group : olanzapine + psychoeducational programme olanzapine alone . In follow 12 week study patient undergo psychoeducational programme . The efficacy programme assess monitor mean difference baseline endpoint total body weight BMI .</brief_summary>
	<brief_title>A Study Induced Weight Gain During Atypical Antipsychotic Treatment Its Management With Psychoeducational Programme</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>All patient , previously treat olanzapine antipsychotic monotherapy , show weight gain increase BMI &gt; 7 % ( assessed routine visit begin antipsychotic treatment ) . Male female subject least 18 65 year age . Subjects must consider reliable . Each subject must level understanding sufficient perform test examination require protocol . Each patient , ( patient 's legal representative mandate local law ) , must understand nature study must sign informed consent document . Exclusion criterion : Serious , unstable illness death anticipate within 1 year intensive care unit hospitalization disease anticipate within 6 month . This include hepatic ( specifically degree jaundice ) , renal , gastroenterologic , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease ( specifically current agranulocytosis absolute neutrophil count &lt; 500 mm3 ) . Prior treatment antipsychotic drug associate olanzapine . Judged clinically significant suicidal homicidal risk and/or agitate enough necessitate use restraint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>